MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support.

We believe in restoring dignity and freedom to patients. We believe in therapies that are designed to integrate seamlessly into people’s daily routines, offering confidence without compromise.

Our marketed flagship drug Wynzora® Cream is more than a drug; it’s a lifelong partner in reclaiming the simplicity and ease of every day for people with plaque psoriasis.

Wynzora® is partnered with leading pharmaceutical companies specialized in dermatology covering more than 40 countries in four continents representing more than 2.6 billion people.

This page is not intended for discussions about products. As such, postings or comments that contain product discussions may be removed. 

This page is for discussions about MC2 Therapeutics and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. 

Please keep in mind that MC2 Therapeutics work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. 

Comments contained on this site come from members of the public, and do not necessarily reflect the views of MC2 Therapeutics.

MC2 Therapeutics

Org chart

Teams

Offices